US 2017/0320957 A1Published application

Methods of Inhibiting Activity Using Anti-CD27 Antibodies

AssigneeJanssen Biotech, Inc.

InventorsJohn Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Claims14

Dependent claims

A method of inhibiting T-cell mediated B-cell antibody production, comprising contacting a portion of the T-cells of a subject with an effective amount of a human CD27 antibody or antigen-binding fragment thereof comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising:

a complementarity determining region light chain 1 (CDRL1) amino acid sequence selected from the group consisting of SEQ ID NOs:
59-66 and 158;
a CDRL2 amino acid sequence selected from the group consisting of SEQ ID NOs:
67-74;
and
a CDRL3 amino acid sequence of SEQ ID NO:
75;
said heavy chain variable region comprising:
a CDRH1 amino acid sequence selected from the group consisting of SEQ ID NOs:
42-45 and 161;
a CDRH2 amino acid sequence selected from the group consisting of SEQ ID NOs:
46-57, 156, and 157;
and
a CDRH3 amino acid sequence of SEQ ID NO:
58, and the antibody or antigen binding portion thereof inhibits the activation of CD27 on said human T-cells in the presence of human CD70 protein or a portion of human CD70 protein.

12 more elements

A method of inhibiting naïve T-cell proliferation, comprising contacting a tissue with an effective amount of a human CD27 antibody or antigen-binding fragment thereof comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising:

a complementarity determining region light chain 1 (CDRL1) amino acid sequence selected from the group consisting of SEQ ID NOs:
59-66 and 158;
a CDRL2 amino acid sequence selected from the group consisting of SEQ ID NOs:
67-74;
and
a CDRL3 amino acid sequence of SEQ ID NO:
75;
said heavy chain variable region comprising:
a CDRH1 amino acid sequence selected from the group consisting of SEQ ID NOs:
42-45 and 161;
a CDRH2 amino acid sequence selected from the group consisting of SEQ ID NOs:
46-57, 156, and 157;
and
a CDRH3 amino acid sequence of SEQ ID NO:
58, and the antibody of antigen binding portion inhibits the activation of CD27 on said human T-cells in the presence of human CD70 protein or a portion of human CD70 protein.

12 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/596,609Filed 16 May 2017
Priority: 15 Mar 2012
Published: 9 Nov 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification23 codes

C07K 16/2878
Against receptors, cell surface antigens or cell surface determinants: against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
A61P 1/00
Drugs for disorders of the alimentary tract or the digestive system
A61P 9/00
Drugs for disorders of the cardiovascular system
A61P 11/00
Drugs for disorders of the respiratory system

Family

Application61/611,332Us provisional application · filed 15 Mar 2012
Application13/835,518Division · filed 15 Mar 2013
Application14/790,144Division · filed 2 Jul 2015
Application15/596,609Division
US 10,301,392 B2Related patent
US 2013/0243795 A1Published application
US 2015/0299330 A1Published application
US 9,102,737 B2Related patent
US 9,683,046 B2Related patent
US 2017/0320957 A1This patent

From the US filing history. Foreign family members aren’t listed.